Research progress on the role and mechanisms of action of sodium-dependent glucose transporter 2 inhibitors in heart failure with preserved ejection fraction / 中华老年医学杂志
Chinese Journal of Geriatrics
;
(12): 113-118, 2023.
Artículo
en Chino
| WPRIM
| ID: wpr-993785
ABSTRACT
Sodium-dependent glucose transporter 2 inhibitors(SGLT2i)are a new class of glucose-lowering drugs, can reduce blood sugar by inhibiting the reabsorption of glucose at the proximal tubule and are widely used in clinical treatment of type 2 diabetes.SGLT2i can not only lower blood sugar, but also offer multiple cardiovascular benefits.Several large randomized controlled trials have confirmed the safety and efficacy of SGLT2i for heart failure with preserved ejection fraction(HFpEF). Herein, we present an overview on advances in SGLT2i for HFpEF.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of Geriatrics
Año:
2023
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS